p.146 抽出テキスト

先天性心疾患,心臓大血管の構造的疾患(structural heart disease) に対するカテーテル治療のガイドライン

38: 3152-3159. PMID: 29029023 920. Olsson KM, Wiedenroth CB, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J 2017; 49: 1602409. PMID: 28596435 921. Brenot P, Jaïs X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53: 1802095. PMID: 31023842 922. 日本循環器学会.2014年版慢性肺動脈血栓塞栓症に対するballoon pulmonary angioplasty の適応と実施法に関するステートメント.https://www.j-circ.or.jp/old/guideline/pdf/JCS2014_ito_d.pdf 923. Kawakami T, Ogawa A, Miyaji K, et al. Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. Circ Cardiovasc Interv 2016; 9: e003318. PMID: 27729418 924. Ejiri K, Ogawa A, Fujii S, et al. Vascular Injury Is a Major Cause of Lung Injury After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ Cardiovasc Interv 2018; 11: e005884. PMID: 30545259 925. Ogawa A, Satoh T, Fukuda T, et al. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Results of a Multicenter Registry. Circ Cardiovasc Qual Outcomes 2017; 10: e004029. PMID: 29101270 926. 日本循環器学会.BPA指導施設・実施医・指導医について. http://www.j-circ.or.jp/BPA/files/BPA_shidousisetsu_jissii_sidoui. pdf 927. 日本循環器学会,日本心不全学会.心筋症診療ガイドライン(2018年改訂版).https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf 928. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214. PMID: 7616800 929. Come PC, Riley MF. Hypertrophic cardiomyopathy. Disappearance of auscultatory, carotid pulse, and echocardiographic manifestations of obstruction following myocardial infarction. Chest 1982; 82: 451-454. PMID: 6889484 930. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 2011; 75: 28-37. PMID: 21116069 931. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e212-e260. PMID: 22075469 932. Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-2779. PMID: 25173338 933. Veselka J, Jensen M, Liebregts M, et al. Alcohol septal ablation in patients with severe septal hypertrophy. Heart 2020; 106: 462-466. PMID: 31471463 934. Maekawa Y, Akita K, Takanashi S. Contemporary Septal Reduction Therapy in Drug-Refractory Hypertrophic Obstructive Cardiomyopathy. Circ J 2018; 82: 1977-1984. PMID: 29910224 935. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118: 131-139. PMID: 18591440 936. Veselka J, Krejčí J, Tomašov P, et al. Survival of patients ≦ 50 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol 2014; 30: 634-638. PMID: 24882534 937. Maekawa Y, Jinzaki M, Anzai A, et al. Successful second attempt multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation for an octogenarian with hypertrophic obstructive cardiomyopathy. Int J Cardiol 2014; 176: e131-e132. PMID: 25150473 938. Maekawa Y, Jinzaki M, Tsuruta H, et al. Multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation in a Noonan syndrome patient with hypertrophic obstructive cardiomyopathy. Int J Cardiol 2014; 172: e79-e81. PMID: 24411913 939. Maekawa Y, Akita K, Tsuruta H, et al. Significant reduction of left atrial volume concomitant with clinical improvement after percuta- neous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy, and its precise detection with multidetector CT. Open Heart 2016; 3: e000359. PMID: 27307994 940. Kim LK, Swaminathan RV, Looser P, et al. Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol 2016; 1: 324-332. PMID: 27438114 941. Bogaert J, Olivotto I. MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology 2014; 273: 329-348. PMID: 25340269 942. Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124: 40-47. PMID: 21670234 943. Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008; 101: 668-673. PMID: 18308018 944. Mitsutake R, Miura S, Sako H, et al. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy. Int J Cardiol 2008; 129: e61-e63. PMID: 17888532 945. Spratt JC, Langrish JP. Identifying the target septal perforator prior to alcohol septal ablation in hypertrophic obstructive cardiomyopathy: a new application for computed tomography coronary angiography. Heart 2011; 97: 1718-1719. PMID: 21807658 946. Krishnaswamy A, Tuzcu EM, Kapadia SR. Use of intraprocedural CT imaging to guide alcohol septal ablation of hypertrophic cardiomyopathy in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2012; 80: 991-994. PMID: 22121082 947. Ghersin E, Soto V, Heldman AW. Multidetector computerized tomography can guide and document alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2011; 123: e5-e7. PMID: 21242503 948. Sherrid MV, Balaram S, Kim B, et al. The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context. J Am Coll Cardiol 2016; 67: 1846-1858. PMID: 27081025 949. Tajima M, Iguchi N, Utanohara Y, et al. Computed tomography imaging to quantify the area of the endocardial subvalvular apparatus in hypertrophic cardiomyopathy - Relationship to outflow tract obstruction and symptoms. J Cardiovasc Comput Tomogr 2016; 10: 351-358. PMID: 27498132 950. Yang DH, Kang JW, Kim N, et al. Myocardial 3-Dimensional Printing for Septal Myectomy Guidance in a Patient With Obstructive Hypertrophic Cardiomyopathy. Circulation 2015; 132: 300-301. PMID: 26216088 951. Hamatani Y, Amaki M, Kanzaki H, et al. Contrast-enhanced computed tomography with myocardial three-dimensional printing can guide treatment in symptomatic hypertrophic obstructive cardiomyopathy. ESC Heart Fail 2017; 4: 665-669. PMID: 29154429 952. Maekawa Y, Jinzaki M, Anzai A, et al. Utility of the reverse wire technique in multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation. Int J Cardiol 2014; 173: e33-e34. PMID: 24708931 953. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-2421. PMID: 9832486 954. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-1755. PMID: 9788829 955. Faber L, Seggewiss H, Welge D, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004; 5: 347- 355. PMID: 15341870 956. Fernandes VL, Nielsen C, Nagueh SF, et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv 2008; 1: 561-570. PMID: 19463359 957. Sorajja P, Ommen SR, Holmes DR Jr, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012; 126: 2374-2380. PMID: 23076968 958. Sorajja P, Binder J, Nishimura RA, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hyper-